Empagliflozin reduced proinflammatory cytokines and oxidative stress markers in INOCA patients with CMD, improving vascular health. Treatment led to favorable shifts in endothelial extracellular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback